Retatrutide liver fat MASLD MASH hepatic steatosis research triple agonist glucagon receptor Durham Peptides Canada Retatrutide's most-cited research data centers on weight reduction — the dramatic 24%+ figures from the Jastreboff 2023 Phase 2 trial. But the same trial included a less-discussed secondary endpoint that may be even more clinically meaningful: hepatic steatosis, measured by MRI-PDFF (proton density fat fraction). The reported liver fat reductions in Retatrutide

Tirzepatide SURMOUNT-OSA sleep apnea research dual agonist GLP-1 GIP Durham Peptides Canada Tirzepatide's clinical research base now spans three large programs — SURPASS for type 2 diabetes, SURMOUNT for weight management, and SURMOUNT-OSA for obstructive sleep apnea. The SURMOUNT-OSA program, published in New England Journal of Medicine in 2024 (Malhotra et al.), established Tirzepatide in a third major research domain that goes beyond glycemic and weight endpoints — examini

Selank stress response HPA axis cortisol tuftsin analog research peptide Durham Peptides Canada Selank's research literature is most often discussed in anxiolytic terms — anxiety reduction in research models like the elevated plus-maze and conditioned-fear paradigms. But there's a more specific and mechanistically interesting research thread within that broader category: stress response research, which examines how Selank affects the HPA (hypothalamic-pituitary-adrenal) axis,

Semax stroke neuroprotection BDNF ACTH 4-10 analog cerebrovascular research Durham Peptides Canada Semax is most commonly discussed as a nootropic research peptide — the cognitive-enhancement angle. But Semax's original and most extensive Russian-language research literature centers on a different application entirely: stroke and neuroprotection research. The compound was developed at the Russian Academy of Sciences specifically for cerebrovascular research applications, and

Wolverine Stack vs Glow Blend BPC-157 TB-500 GHK-Cu research peptide blend comparison Durham Peptides Canada The Wolverine Stack and the Glow Blend are the two recovery-focused multi-component formulations in the Durham Peptides catalog. They overlap mechanistically — both contain BPC-157 and TB-500 — but the Glow Blend adds GHK-Cu as a third component, fundamentally changing what the formulation is studied for. The choice between them comes down to a specific question: does

CagriSema REIMAGINE 2 type 2 diabetes research cagrilintide semaglutide amylin GLP-1 Durham Peptides Canada CagriSema's most-cited research data — REDEFINE 1, published in NEJM 2025 — examined the cagrilintide-plus-semaglutide combination in weight management research. But CagriSema's clinical development also includes the REIMAGINE 2 program, studying the same combination in type 2 diabetes research specifically. The February 2026 REIMAGINE 2 readout produced one of the more

Tirzepatide SURPASS type 2 diabetes research dual agonist GLP-1 GIP Durham Peptides Canada Most current discussion of Tirzepatide centers on weight management research, anchored in the SURMOUNT clinical trial program. But Tirzepatide's original and largest clinical development program was SURPASS — a multi-trial program studying Tirzepatide in type 2 diabetes research models, not weight management. The dual GLP-1/GIP receptor mechanism that drives weight effects also drives g

GLOW Blend components GHK-Cu BPC-157 TB-500 three peptide skin recovery research Durham Peptides Canada The GLOW Blend is one of Durham Peptides' flagship multi-component formulations — a three-peptide blend combining GHK-Cu, BPC-157, and TB-500 in a single co-lyophilized vial for skin and recovery research. Most existing coverage of GLOW treats it as a whole, which is fine for understanding what the blend is for, but misses the more useful question: what does each of the thr

GHK-Cu copper peptide hair follicle dermal papilla research peptide Durham Peptides Canada GHK-Cu's research story spans skin biology, wound healing, and anti-inflammatory research, but one of its most well-developed and distinctive application areas is hair follicle research specifically. The copper tripeptide's investigated effects on hair follicle biology — and particularly on the dermal papilla (the signaling center at the base of each hair follicle) — make it one of the

NAD+ sirtuins SIRT1 SIRT3 longevity research coenzyme enzyme relationship Durham Peptides Canada NAD+ is the most-studied longevity-research coenzyme. Sirtuins are the most-studied longevity-research enzyme family. The reason they appear in the same conversation so often isn't coincidence — it's biology. Sirtuins literally cannot function without NAD+. They consume NAD+ as a substrate for every reaction they catalyze, which means NAD+ availability is the rate-limiting factor

CJC-1295 No DAC vs DAC half-life pulsatile sustained GH release research peptide comparison Durham Peptides Canada Researchers looking at CJC-1295 quickly encounter a confusing reality: there are actually two different CJC-1295 compounds — "CJC-1295 with DAC" and "CJC-1295 without DAC" (also called "Mod GRF 1-29" or simply "CJC-1295 No DAC"). They share most of their structure but have one critical difference that produces dramatically different research profiles. Durham Pept

TB-500 thymosin beta-4 fragment tendon ligament connective tissue research peptide Durham Peptides Canada TB-500's research literature spans multiple tissue types, but its most-developed application area is tendon and ligament research — the connective tissues that link muscle to bone (tendons) and bone to bone (ligaments). This isn't accidental: tendons and ligaments are notoriously slow-healing tissues with limited vascular supply and low cellular turnover, and the specific

MOTS-c AMPK mechanism mitochondrial-derived peptide energy metabolism longevity research Durham Peptides Canada MOTS-c sits in an unusual place in the research peptide landscape — most peptides are encoded by nuclear DNA and produced through standard ribosomal translation, but MOTS-c is encoded within mitochondrial DNA, making it part of a small and biologically distinctive class of mitochondrial-derived peptides. That origin is interesting on its own, but the more important

Ipamorelin selectivity selective GH release cortisol prolactin GHRP research peptide Durham Peptides Canada Ipamorelin is often introduced as "a growth hormone secretagogue" or "a GHRP," which describes what category it sits in but misses the single most defining property of the compound: its selectivity. Ipamorelin was designed specifically to release growth hormone without the off-target hormonal effects (cortisol, prolactin, aldosterone) that older GHRPs produced. That sel

Epithalon telomerase mechanism Ala-Glu-Asp-Gly tetrapeptide pineal longevity research Durham Peptides Canada Epithalon's research story has a single mechanistic anchor that distinguishes it from almost every other research peptide in the longevity category: investigated telomerase activation. Most longevity peptides work through pathways that influence cellular metabolism, mitochondrial function, gene expression, or growth-factor signaling. Epithalon's research literature uni

Wolverine Stack BPC-157 TB-500 1:1 ratio angiogenesis cell migration research peptide blend Durham Peptides Canada The Wolverine Stack combines BPC-157 and TB-500 at a 1:1 ratio — 5 mg of each peptide in a 10 mg total vial — and that proportion isn't arbitrary. It reflects a specific mechanistic logic about how angiogenesis and cell migration interact in tissue repair research, plus a practical research reality about how these two compounds are studied together in published l

KPV tripeptide skin research dermatological anti-inflammatory alpha-MSH Durham Peptides Canada KPV's research literature spans inflammatory bowel models, systemic inflammation, and dermatological research — but the gut/IBD angle has dominated most coverage of the compound. The skin-research angle is genuinely distinct, deserves its own treatment, and is increasingly relevant given KPV's inclusion in skin-focused research blends like KLOW. This article focuses specifically on

CagriSema components cagrilintide amylin semaglutide GLP-1 individual contributions Durham Peptides Canada CagriSema is one of the most-watched combination research peptides of 2026 — a fixed blend of cagrilintide and semaglutide that pairs two compounds with completely different receptor mechanisms in a single vial. Most coverage of CagriSema treats it as a whole, which is fine for understanding the headline weight-loss data but misses the more interesting question: what doe

Tirzepatide vs Retatrutide dual agonist triple agonist GLP-1 GIP glucagon comparison Durham Peptides Canada Tirzepatide and Retatrutide are the two single-molecule multi-agonists currently in the Durham Peptides catalog — Tirzepatide as the established dual agonist (GLP-1 + GIP) with extensive Phase 3 data, and Retatrutide as the newer triple agonist (GLP-1 + GIP + glucagon) with the most aggressive multi-receptor design in current metabolic peptide research. Researchers comp

Retatrutide vs Semaglutide triple agonist GLP-1 metabolic research peptide comparison Durham Peptides Canada Retatrutide and Semaglutide are the two endpoints of the modern metabolic peptide spectrum — Semaglutide as the established single-receptor GLP-1 agonist that defined the GLP-1 era, and Retatrutide as the newest single-molecule triple agonist engaging three receptors at once. Researchers comparing them are essentially asking: what does adding GIP and glucagon to the GL